Designing a Novel Cancer Drug: From Hit ID to Candidate
Supported by:
14 March 2017
Many cancers exhibit dysregulation of the MAPK/ERK (MEK) signalling pathway driven by mutations in multiple enzymes within the pathway. Listen to our scientists describe a project to identify a novel, potent, selective small-molecule inhibitor targeting a specific kinase in this pathway.
Discover how their multidisciplinary approach to hit ID, design and synthesis of novel chemical templates and development of targeted in vitro and in vivo assays resulted in the nomination of the first development candidate in just over two years.
KEYNOTE SPEAKERS
- Steve Price, PhD, Executive Director, Chemistry & Project Management, Discovery, Charles River
- Peter Lockey, MSc, PhD, Director, Integrated Drug Discovery, Charles River
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
